FDA Approved: BIKTARVY — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for BIKTARVY, a fixed-dose combination HIV-1 therapy from Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

SUPPL AP for BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)